CRMA-1001 CRISPR therapy enters human trials for hepatitis B
An experimental therapeutic named CRMA-1001 is advancing clinical evaluations for hepatitis B, deploying a modified CRISPR technology to attach chemical tags to viral DNA inside liver cells without cutting the … Read More